17 предвид относително дългия полуживот на активното вещество след спиране на пероралния рисперидон.
The need for increased patient monitoring during the switch period was discussed and the CHMP considered that the data provided showed no worsening in clinical symptoms after the therapy with long-acting risperidone was initiated.